Natera's Q3 revenue jumps 34%, lifts 2026 revenue guidance by $140M
Natera reported Q3 revenue of $794M, up about 34% year over year, and raised its full-year 2026 revenue guidance to $3.005B-$3.035B, per TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Natera's third-quarter revenue rose about 34% year over year to $794 million, according to TradingView. The company attributed the growth to higher test volumes, led by oncology. Total tests exceeded 1.09 million, and clinical MRD volume grew more than 56%.
The company raised its fiscal 2026 revenue guidance to a range of $3.005 billion to $3.035 billion, an increase of $140 million at the midpoint. The quarterly net loss narrowed to $59.9 million. Natera also set a 2029 revenue target of $6 billion.
why it matters
For investors, the combination of faster revenue growth, a higher full-year outlook and a smaller loss points to a business that is scaling. The figures come from a short summary published by TradingView rather than the company's original filing, so key numbers should be checked against the official report.
market impact
Natera shares: stronger revenue and higher guidance support the stock
- Natera shares (NTRA) pressure up — revenue growth and a raised outlook above expectations signal a stronger business
tags
instruments
sources
- NTRA: Q3 revenue rose 34%, and FY 2026 revenue guidance increased by $140M at midpoint — TradingView, 5 November 2026 at 21:09 UTC
- NTRA: Q3 revenue rose 34%, and FY26 revenue guidance increased by $140M at midpoint — TradingView, 5 November 2026 at 21:20 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗